Literature DB >> 12210802

Normokalemic periodic paralysis revisited: does it exist?

Patrick F Chinnery1, Timothy J Walls, Michael G Hanna, David Bates, Peter R W Fawcett.   

Abstract

Normokalemic periodic paralysis (normoKPP) is well established in the literature, but there are doubts as to whether it exists as a discrete entity. Retrospective clinical and molecular analysis has confirmed suspicions that most normoKPP families actually have a variant of hyperkalemic periodic paralysis (hyperKPP) due to a mutation of the muscle-specific sodium channel gene (SCN4A). However, the original normoKPP family described by Poskanzer and Kerr (Poskanzer DC, Kerr DNS. A third type of periodic paralysis, with normokalemia and favourable response to sodium chloride. Am J Med 1961;31:328-342) has remained unchallenged. We identified the Met1592Val mutation of SCN4A in an affected descendent of this original normoKPP family. This is the final piece in the puzzle: normoKPP is actually a variant of hyperKPP and is not a distinct disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210802     DOI: 10.1002/ana.10257

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  16 in total

1.  Enhanced slow inactivation of the human skeletal muscle sodium channel causing normokalemic periodic paralysis.

Authors:  Lei Wu; Baorong Zhang; Ying Kang; Weiping Wu
Journal:  Cell Mol Neurobiol       Date:  2014-03-29       Impact factor: 5.046

2.  Depolarization-activated gating pore current conducted by mutant sodium channels in potassium-sensitive normokalemic periodic paralysis.

Authors:  Stanislav Sokolov; Todd Scheuer; William A Catterall
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

Review 3.  Skeletal muscle channelopathies: new insights into the periodic paralyses and nondystrophic myotonias.

Authors:  Daniel Platt; Robert Griggs
Journal:  Curr Opin Neurol       Date:  2009-10       Impact factor: 5.710

Review 4.  Genotype-phenotype correlation and therapeutic rationale in hyperkalemic periodic paralysis.

Authors:  Karin Jurkat-Rott; Frank Lehmann-Horn
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 5.  Clinical evaluation of membrane excitability in muscle channel disorders: potential applications in clinical trials.

Authors:  James C Cleland; Eric L Logigian
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

Review 6.  Skeletal Muscle Channelopathies.

Authors:  Lauren Phillips; Jaya R Trivedi
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

7.  Targeted mutation of mouse skeletal muscle sodium channel produces myotonia and potassium-sensitive weakness.

Authors:  Lawrence J Hayward; Joanna S Kim; Ming-Yang Lee; Hongru Zhou; Ji W Kim; Kumudini Misra; Mohammad Salajegheh; Fen-fen Wu; Chie Matsuda; Valerie Reid; Didier Cros; Eric P Hoffman; Jean-Marc Renaud; Stephen C Cannon; Robert H Brown
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

8.  Mutations of sodium channel alpha-subunit genes in Chinese patients with normokalemic periodic paralysis.

Authors:  Guo Xiuhai; Wu Weiping; Zhu Ke; Wang Hongbin; Si Yiling
Journal:  Cell Mol Neurobiol       Date:  2007-11-29       Impact factor: 5.046

9.  Transient compartment-like syndrome and normokalaemic periodic paralysis due to a Ca(v)1.1 mutation.

Authors:  Chunxiang Fan; Frank Lehmann-Horn; Marc-André Weber; Marcin Bednarz; James R Groome; Malin K B Jonsson; Karin Jurkat-Rott
Journal:  Brain       Date:  2013-11-15       Impact factor: 13.501

10.  Physiological basis for muscle stiffness and weakness in a knock-in M1592V mouse model of hyperkalemic periodic paralysis.

Authors:  Shiemaa Khogali; Brooke Lucas; Tarek Ammar; Danica Dejong; Michael Barbalinardo; Lawrence J Hayward; Jean-Marc Renaud
Journal:  Physiol Rep       Date:  2015-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.